The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2025 | The importance of early identification of kidney impairment in patients with newly diagnosed myeloma
In this video, Nelson Hamerschlak, MD, PhD, Albert Einstein Israelite Hospital, São Paulo, Brazil, briefly discusses the importance of identifying patients with newly diagnosed multiple myeloma (MM) who may be at risk of kidney failure. Early detection of these patients is crucial to allow for appropriate management strategies to be put into place to prevent kidney failure from occurring. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
As you know, multiple myeloma normally comes to the hematologist due to bone disease or anemia or renal or kidney failure. So when they come with kidney failure, they have to be treated fast to improve their condition. And today we consider people with light-chain high immunoglobulin levels to be treated as soon as we detect them, so we can treat them before they get kidney failure...
As you know, multiple myeloma normally comes to the hematologist due to bone disease or anemia or renal or kidney failure. So when they come with kidney failure, they have to be treated fast to improve their condition. And today we consider people with light-chain high immunoglobulin levels to be treated as soon as we detect them, so we can treat them before they get kidney failure.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Lectures to: Kite, Novartis, Janssen; AB: Pfizer.
